Company Encyclopedia
View More
name
Aldeyra Therap
ALDX.US
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases.
1.946 T
ALDX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aldeyra Therapeutics: Promising Advancements and Strategic Positioning Drive Buy Rating

    H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating for Aldeyra Therapeutics (ALDX) due to promising advancements in their RASP modulator platform and resolution of manufacturing issues with Reproxalap. The PDUFA date for Reproxalap is set for December 2025, with potential FDA approval and a licensing agreement with AbbVie. BTIG also maintained a Buy rating with a $9.00 price target.

    Tip Ranks·
    US
    ALDX
    +0.21%
    Tip Ranks·
    US
    ALDX
    +0.21%

    Promising Developments and Regulatory Progress Drive Buy Rating for Aldeyra Therapeutics

    Thomas Shrader from BTIG maintained a Buy rating on Aldeyra Therapeutics with a price target of $9.00 due to promising developments and regulatory progress. Aldeyra's systemic RASP inhibitors show potential for Parkinson's and Multiple Sclerosis. The FDA accepted their NDA for Reproxalap after a successful Phase 3 trial for dry eye disease. ALDX's price increased by 141.35% in six months.

    Tip Ranks·
    US
    ALDX
    +0.21%
    Tip Ranks·
    US
    ALDX
    +0.21%

    Aldeyra Therapeutics Showcases Broad Immunology Pipeline Targeting Immune-Mediated Diseases in New R&D Presentation

    Aldeyra Therapeutics presented an update on its R&D pipeline, highlighting progress in immune-mediated disease programs. Key developments include reproxalap for dry eye disease, ADX-248 and ADX-246 for atopic dermatitis, and ADX-2191 for primary vitreoretinal lymphoma. ADX-629 showed activity in Phase 2 trials for autoimmune diseases. The company reported $75.3 million in cash, funding operations into 2027. The presentation was published on November 12, 2025.

    Reuters·
    US
    ALDX
    +0.21%
    Reuters·
    US
    ALDX
    +0.21%

    Aldeyra Therapeutics Expands RASP Platform in 2025 Webcast

    Aldeyra Therapeutics announced updates during its 2025 Research & Development Webcast, including the expansion of its RASP platform to address central nervous system diseases and manufacturing updates on reproxalap for dry eye disease. The webcast highlighted ongoing clinical trials and regulatory plans. Analysts have mixed views on ALDX stock, with a recent Buy rating and a $9.00 price target, while TipRanks' AI Analyst rates it as Underperform due to financial and regulatory challenges.

    Tip Ranks·
    US
    ALDX
    +0.21%
    Tip Ranks·
    US
    ALDX
    +0.21%

    Aldeyra Therapeutics to Join Jefferies Global Healthcare Conference in London

    Aldeyra Therapeutics Inc. will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on November 20, 2025. President and CEO Todd C. Brady will discuss the company’s activities with Clara Dong, Vice President at Jefferies. This announcement is for informational purposes only and should not be interpreted as financial, investment, or legal advice.

    Reuters·
    US
    ALDX
    +0.21%
    Reuters·
    US
    ALDX
    +0.21%
    © 2025 Longbridge｜Disclaimer